Companies
Algen is using CRISPR to uncover disease-driving RNA messages to find treatments for cancer, inflammation and diseases with high unmet needs. We are harnessing the power of CRISPR and machine learning to find first-in-class drugs that modulate RNA messages at single-cell resolution. Algen's founders are bioengineer from Jennifer Doudna Lab and biotech commercialization expert, teamed up with experienced pharmaceutical executives.
AlgoSurg makes AI software solutions, for various next-generation surgical applications ranging from Robotics-surgeries, AR-based-navigation/training, cloud-based 3D surgery planning and automatic patient-specific instrument/implant design.
Allotrope Medical is a Houston-based medical device company founded and run by the surgeon that created the technology. Our platform stimulation technology gives physicians control over the natural movements of the urinary and digestive systems. This control over smooth muscle tissues allows the surgeon to identify hidden anatomic structures (ureters, sphincters and others), determine tissue health, and even assist in diagnosing disease states. The technology is delivered through the surgeon's existing instruments (which have remained unchanged in over 30 years) giving a completely new capability to the surgeon while maintaining seamless workflow integration. With an $600M (and growing) initial market, the technology is future-proof and is readily able to be integrated into the continued advancements in the surgical space.
Almond is like One Medical but for women’s health: we make it easy to get great ObGyn care fast, both at our in-person offices and over telehealth. The problem with traditional ObGyn practices is that physician time is misused, so patients get slow care. We're rebuilding back-office tech that saves physicians time, and we're hiring a wider range of care providers roles, which let us deliver better outcomes to patients and reduce the amount of time it takes to get their issue resolved.
Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. We know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. With our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.
Amby Health automates billing and quality reviews for ambulance agencies (EMS), replacing large back-office teams with AI. We analyze patient reports in seconds—not months—accurately coding claims and identifying liability and care risks while eliminating costly, error-prone manual processes.
Design, simulate, and test your proteins 100x faster with the end-to-end no-code platform for protein engineering. Powered by Amina, our AI agent. With Amina, one protein engineer can do the work of 10. Describe what you want to achieve and Amina will handle everything else – from research and design to simulation, folding, docking, and protein characterization. It asks clarifying questions if needed, intelligently understands and performs the task, and analyzes your results within the context of your project.
Growing old is part of life. Losing your independence shouldn't be. We believe in a world where seniors can keep their freedom and still feel safe. That's why we created Amulyte; a remote monitoring and activity tracking system for seniors. Amulyte is committed to providing the technology needed to help protect seniors from falls so they can continue to age at home. There are 55 million seniors in North America, a number that is only going to grow in the coming years. It is becoming increasingly important that seniors are able to continue living in their own homes as they age. Amulyte helps make that possible by using the latest technology to provide coverage anywhere - no more base station or being restricted to your home.
Building a standard-of-care medical device to freeze abnormal cells before they become cervical cancer, in any clinic, anywhere in the world, at 1/10 the cost. -- Ananya Health is building a portable cryoablation unit designed for every primary care clinic in the world. Our beachhead application is cervical cancer prevention -- even though cervical cancer is easy to screen for, 80% of clinics worldwide lack the infrastructure and specialized staff to treat at the earliest stages. Our platform technology allows nurses and lower level health workers to treat at the point of care for 1/10 the cost of traditional ablation, and is the only cryo device that will help us achieve the WHO target to eliminate cervical cancer in our lifetime.
We're building autonomous robots to make surgery safe, easier and more efficient. Robots currently perform about 1/4 of surgeries but only help with the physical aspects. We use AI to make surgery cognitively easier. This has far greater potential to improve outcomes and reduce costs. Founded by 3x founders from medtech and autonomous vehicles, we're on track to be the fastest surgical robot to market of all time. First indication is prostate enucleation.
Andson Biotech helps pharmaceutical companies measure difficult to detect chemicals that they need to measure while developing and manufacturing drugs like cell-therapies or biologics. Drug companies want to use our technologies to get fast and accurate chemical measurements they do thousands of times per day for drug development and quality control.
Andy is AI software that completes documentation for nurses doing home visits. Our software saves $8B a year; Tiantian was previously a PM at Google’s healthcare business and Max was a staff engineer on the health team at Apple. Andy benefits nurses and the agencies that employ them. Agencies that use Andy see up to 45% more detailed charts, 2x greater nurse productivity, and timely submission (no more billing delays!) With Andy, clinicians get their evenings back. Home health is the fastest growing segment of healthcare, doubling to $251B by 2031. Combined with recent nursing shortages and burnout, we’re seeing not just urgency, but excitement and joy, around adopting AI for home health.
Hey, thanks for reading! We founded Anima out of a very personal problem. Again and again, we saw people dying because they got bad care plans, weeks or months late. We build Care Enablement for care teams - combining online consultation with productivity tools in a realtime multiplayer dashboard. By doing this, we get people optimal care within 24 hours.
Adoption of Telehealth 1.0 has dropped to <5% because it's inefficient and unintelligent. Ankr uses generative AI to recreate functions of clinic staff including front desk, medical assistants and scribe. This allows Doctors to "spin-up" virtual clinics on-demand, anytime, anywhere. An average clinic using Ankr generates $1M in new revenue/year. We integrate with all top EHRs and work with all types of clinics in mid- to large-sized healthcare organizations.
Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods. Currently, DNA is manufactured via a chemical method that has remained mostly unchanged for 35 years. Our enzyme-based approach promises to dramatically accelerate innovation in biological research and biotechnology, including therapeutics, diagnostics and biomanufacturing.
Proteins power everything from the cells in your body to creating materials you rely on every day—but until now, we’ve been forced to discover their functions by trial and error. Designing a new therapeutic can take decades and billions of dollars, and even our best industrial catalysts work at a snail’s pace compared to their theoretical optimums. Anthrogen is changing that. By training massive AI foundation models on protein sequences and structures, we’ve unlocked the ability to generate—on demand—completely novel molecular machines with atomic-level precision. Simply describe the function you need, and our platform imagines the peptide or protein that will deliver it. We're building models to speed up billions of years of evolution into the span of an afternoon's worth of compute. The result? New-to-nature therapies, ultra-efficient catalysts for sustainable manufacturing, and a whole new frontier of molecular innovation—designed as precisely as any cutting-edge aircraft or microchip.
Anto Biosciences is building the first foundation model for microbial communities, making the gut microbiome computable for the first time. We predict drug toxicity and efficacy across diverse populations and fix drugs so they work for everyone — solving the hidden root cause of most drug failures. Founded by Arvid (Broad Institute of MIT and Harvard; Nature-published researcher who pioneered quality-aware, goal-directed sparsification) and David (Harvard Medical School Gastroenterology, J&J), second-time founders who published the breakthrough at leading machine learning AI conferences and Nature. We've caught a $1B cancer drug that worked in China but failed clinical trials in the U.S. With the help of our model, we are the first ones to know exactly why. Anto is backed by Y Combinator (F25). https://www.anto.bio/
We help healthcare companies run their practices. Eligibility, BI, claims, patient payments? Shoot us an email at founders@aperohealth.com Apero is a Y-Combinator-backed startup based in San Francisco bringing transparency and ease to medical billing. As one of the top startups from the Summer 2019 Y Combinator batch, we have raised from well-known investors including the creator of Gmail Paul Buchheit and the founders of Doctor on Demand, Gusto and Reddit, and serve startups that have raised over $1B in Venture Capital. The founding team are Stanford CS and Berkeley grads and include the CTO of Doctor on Demand having helped raised $240m and process millions of video calls. We are also hiring for engineers and product-minded operations people interested in giving price transparency to patients and providers. We serve practices nationwide, and integrate with leading EHRs as well.
Archform is teeth aligner software startup that lets orthodontists create, design and 3D print aligners within their own offices. The idea is to provide orthodontists with a way to better compete against some direct-to-consumer teeth aligner startups and cut down on the cost of Invisalign.
Argon AI is a platform where biopharma and life sciences professionals can execute complex and data driven workflows using natural language. We help professionals get thorough answers to questions about clinical trials, existing treatments, healthcare landscape, and the competitive market in minutes rather than months. Prior to starting Argon, Samy was responsible for Flatiron Health’s (Roche) first data analytics project which eventually led to the start of the Flatiron Services business unit. There, he saw first-hand the heavily manual process that biopharma companies struggle through to get the insights they need to drive forward their drug development programs. He also helped close over $6M+ in ARR and is an expert in enterprise pharma sales. Cyrus previously led engineering teams and built 0 to 1 across pre-seed and unicorn startups, managed mission-critical trade generation systems at Bridgewater, and held AI advisory roles at various startups. Cyrus has a duel degree in EE and CS from USC. Breakthroughs in AI present an opportunity to reinvent biopharma and life science workflows to reduce the time and cost of bringing treatments to patients where delays in bringing a drug to market can cost a pharma company $3M / day.
At Arini, we’re building the operating system for dental groups. Phones are the backbone of dental operations — 80% of appointments are still booked over the phone — yet practices miss 20–30% of inbound calls. That’s millions in lost revenue every month. Patient engagement is the biggest bottleneck to growth in dentistry, and we’ve built the most comprehensive AI-powered patient engagement suite in the industry. Arini manages calls, texts, and bookings. We’re going after a $220B, overlooked industry that still runs on legacy systems and outdated workflows. Arini is bringing AI to every part of the dental stack.